<DOC>
	<DOCNO>NCT00886925</DOCNO>
	<brief_summary>The purpose study determine whether administration albumin addition standard care effective treatment episode hepatic encephalopathy patient cirrhosis .</brief_summary>
	<brief_title>Efficacy Albumin Acute Encephalopathy Patients With Cirrhosis</brief_title>
	<detailed_description>Hepatic encephalopathy frequent complication cirrhosis usually associate poor prognosis . The common presentation acute episode hepatic encephalopathy precipitate factor increase exposure brain ammonia . Current therapy base measure decrease plasma ammonia counteract effect factor infection electrolyte 's disturbance . Brain edema abnormality cerebral blood flow appear important . Part impairment astrocyte function could relate increase oxidative stress injury . In patient cirrhosis hepatic encephalopathy , concentration albumin plasma usually low . Administration human albumin patient hepatorenal syndrome spontaneous bacterial peritonitis major impact prognosis complication . Albumin prevent circulatory dysfunction renal failure . The mechanisms action may include maintenance oncotic pressure scavenger effect toxic substance present blood . Albumin also show beneficial effect neurological injury secondary stroke , probably relation scavenger effect . The administration intravenous albumin patient hepatic encephalopathy may beneficial effect course encephalopathy .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Brain Diseases</mesh_term>
	<mesh_term>Hepatic Encephalopathy</mesh_term>
	<criteria>Cirrhosis liver Hepatic encephalopathy stage &gt; 1 Completion standardize protocol investigate precipitate factor Informed consent next keen Pregnancy Terminal liver disease ( advanced liver disease performance status 34 prior episode acute encephalopathy ) Need advance life support ( mechanical ventilation , ionotropic support , dialysis ) Need albumin administration ( e.g . bacterial spontaneous peritonitis ) Contraindication albumin administration ( e.g . cardiac failure )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Hepatic encephalopathy</keyword>
	<keyword>Cirrhosis</keyword>
	<keyword>Albumin</keyword>
</DOC>